Personalized chemo selection for advanced colorectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests whether a functional test on a tumor biopsy can help choose the best first chemotherapy regimen (FOLFOX or FOLFIRI) for people with metastatic colorectal cancer. It aims to improve outcomes by matching treatment to each person's unique tumor biology.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older
- You have colorectal cancer that has spread and cannot be surgically removed
- Your doctor considers both FOLFOX and FOLFIRI chemotherapy as equally good first options for you
- You have a tumor that can be biopsied (sampled)
- You must be able to start chemotherapy within 28 days of referral
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether using the Oncogramme® device to guide the first-line treatment improves care for people with metastatic colorectal (colon/rectum) cancer. If the device helps pick the most suitable standard chemotherapy plan, it could lead to better outcomes than choosing without it.
This trial tests new treatment combinations for colorectal cancer that has spread (metastatic). It is for people whose cancer is mismatch repair proficient (pMMR) or microsatellite stable (MSS) and who have not had previous treatment for metastatic disease.
This trial tests a combination of immunotherapy (sintilimab), a targeted therapy (cetuximab), and chemotherapy as a first treatment for advanced colorectal cancer that hasn't spread or come back after earlier treatment. It's for people whose tumors have certain genetic markers (RAS/BRAF wild-type) and show signs of immune activity (PD-L1 or CD8+ TILs).
This trial tests a combination of a targeted therapy pill (TKI) and an immunotherapy (PD-1 inhibitor) for people with advanced colorectal cancer that has stopped responding to standard treatments. It uses a blood test to tailor the treatment, aiming to be more effective with fewer side effects.
This trial tests a combination of three chemotherapy drugs plus a targeted therapy as a first treatment for advanced colorectal cancer. The goal is to see if this strong drug mix can shrink tumors better than standard approaches.
This trial tests a combination of two chemotherapy drugs, levozolinate and 5-FU, given together as a first treatment for advanced colorectal cancer that cannot be surgically removed. It aims to see if giving them at the same time works better for patients who have never received treatment for this stage of cancer.
Hear when a new Organoids trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.